Pharmacokinetics of zileuton and its metabolites in patients with renal impairment

Journal of Clinical Pharmacology

Volumn 37, Issue 5, 1997, Pages 395-404

  Awni, Walid M ^a   Wong, Shekman ^a   Chu, Sou Yie ^a   Patterson, Karen ^a   Hansen, Robert ^a   Machinist, Joseph M ^a   Drajesk, Jeff ^a   Keane, William F ^b   Halstenson, Charles E ^b  

^a ABBOTT LABORATORIES   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DRUG METABOLITE; ZILEUTON;

ADULT; ASTHENIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG GLUCURONIDATION; DRUG PROTEIN BINDING; DRUG SAFETY; FEMALE; HEADACHE; HEMODIALYSIS; HUMAN; HUMAN EXPERIMENT; KIDNEY FAILURE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; REVIEW; VERTIGO;

EID: 0030995469     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04317.x     Document Type: Review

References (9)

1. Samuelsson B: Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220:568-575.
2. Samuelsson B, Dahlen S, Lindgren J, Rouzer CA, Serhan CN: Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987;237:1171-1176.
3. Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegal SC, et al: The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993;119:1059-1066.
4. Wong SL, Awni WM, Cavanaugh JH, El-Shourbagy T, Locke C, Dube LM: The pharmacokinetics of single oral doses of zileuton 200 to 800 mg, its enantiomers, and its metabolites, in normal healthy volunteers. Clin Pharmacokinet 1995;29(suppl):9-21.
5. Awni WM, Braeckman RA, Granneman GR, Witt G, Dube LM: Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600 mg in healthy volunteers. Clin Pharmacokinet 1995; 29(suppl):22-33.
6. Awni WM, Locke CS, Dube LM, Cavanaugh JH: Evaluation of the diurnal variation in the pharmacokinetics of zileuton in healthy volunteers. J Clin Pharmacol 1997;37:388-394.
7. Machinist JM, Kukulka MJ, Bopp BA: In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite. Clin Pharmacokinet 1995;29(suppl):34-41.
8. Mayer MD, Kukulka MJ, Amann MT, Machinist JM: Human in vivo and in vitro metabolism of zileuton. Proceedings of the 7th North American ISSX Meeting, San Diego, CA. ISSX Proceedings. 1996;10:315.
9. Granneman GR, Braeckman RA, Erdman KA: Determination of a New 5-lipoxygenase inhibitor, zileuton, and its inactive N-dehydroxyated metabolite in plasma by high performance liquid chromatography. Clin Pharmacokinet 1995;29(suppl):1-8.